Stock Track | Corcept Therapeutics Soars on Strong Growth Prospects

Stock Track11-07

Corcept Therapeutics Inc. (CORT) saw its shares surge by 5.04% on November 6th, 2024, driven by the company's impressive financial performance and growth prospects.

The biopharmaceutical company, which specializes in the discovery and development of drugs for endocrinologic, oncologic, metabolic, and neurologic disorders, has been on a remarkable run this year. As of November 5th, CORT's stock has gained a staggering 60.5% year-to-date.

One of the key drivers behind this surge is the massive demand for Corcept's flagship drug, Korlym, which is approved for treating Cushing's syndrome. The company is also expecting to file a new drug application for its lead candidate, relacorilant, to treat Cushing's syndrome in the fourth quarter of 2024.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1179175637?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-07 01:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1179175637","market":"us","top_or_hot":-1,"title":"Stock Track | Corcept Therapeutics Soars on Strong Growth Prospects","media":"Stock Track","content":"<p>Corcept Therapeutics Inc. (CORT) saw its shares surge by 5.04% on November 6th, 2024, driven by the company's impressive financial performance and growth prospects.</p>\n\n<p>The biopharmaceutical company, which specializes in the discovery and development of drugs for endocrinologic, oncologic, metabolic, and neurologic disorders, has been on a remarkable run this year. As of November 5th, CORT's stock has gained a staggering 60.5% year-to-date.</p>\n\n<p>One of the key drivers behind this surge is the massive demand for Corcept's flagship drug, Korlym, which is approved for treating Cushing's syndrome. The company is also expecting to file a new drug application for its lead candidate, relacorilant, to treat Cushing's syndrome in the fourth quarter of 2024.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Corcept Therapeutics Soars on Strong Growth Prospects</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Corcept Therapeutics Soars on Strong Growth Prospects\n</h2>\n\n<h4 class=\"meta\">\n\n2024-11-07 01:52 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Corcept Therapeutics Inc. (CORT) saw its shares surge by 5.04% on November 6th, 2024, driven by the company's impressive financial performance and growth prospects.\nThe biopharmaceutical company, ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CORT","symbol_name":"Corcept医疗","start_time":0,"source_url":"","article_id":"1179175637","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1179175637","pubTimestamp":1730915543,"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Corcept Therapeutics Inc.  saw its shares surge by 5.04% on November 6th, 2024, driven by the company's impressive financial performance and growth prospects.The biopharmaceutical company, which specializes in the discovery and development of drugs for endocrinologic, oncologic, metabolic, and neurologic disorders, has been on a remarkable run this year. As of November 5th, CORT's stock has gained a staggering 60.5% year-to-date.One of the key drivers behind this surge is the massive demand for ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CORT":"Corcept医疗"},"translate_title":"股票赛道Corcept Therapeutics因强劲的增长前景而飙升","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CORT":1},"content_text":"Corcept Therapeutics Inc. (CORT) saw its shares surge by 5.04% on November 6th, 2024, driven by the company's impressive financial performance and growth prospects.\nThe biopharmaceutical company, which specializes in the discovery and development of drugs for endocrinologic, oncologic, metabolic, and neurologic disorders, has been on a remarkable run this year. As of November 5th, CORT's stock has gained a staggering 60.5% year-to-date.\nOne of the key drivers behind this surge is the massive demand for Corcept's flagship drug, Korlym, which is approved for treating Cushing's syndrome. The company is also expecting to file a new drug application for its lead candidate, relacorilant, to treat Cushing's syndrome in the fourth quarter of 2024.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1179175637"}